116 related articles for article (PubMed ID: 37139547)
1. In-silico identification of novel DDI2 inhibitor in glioblastoma
Roy PK; Majumder R; Mandal M
J Biomol Struct Dyn; 2024 Mar; 42(5):2270-2281. PubMed ID: 37139547
[TBL] [Abstract][Full Text] [Related]
2. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.
Koizumi S; Irie T; Hirayama S; Sakurai Y; Yashiroda H; Naguro I; Ichijo H; Hamazaki J; Murata S
Elife; 2016 Aug; 5():. PubMed ID: 27528193
[TBL] [Abstract][Full Text] [Related]
3. Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Northrop A; Vangala JR; Feygin A; Radhakrishnan SK
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31947743
[TBL] [Abstract][Full Text] [Related]
4. Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.
Collins GA; Sha Z; Kuo CL; Erbil B; Goldberg AL
J Biol Chem; 2022 May; 298(5):101875. PubMed ID: 35358511
[TBL] [Abstract][Full Text] [Related]
5. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
6. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
[TBL] [Abstract][Full Text] [Related]
7. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Op M; Ribeiro ST; Chavarria C; De Gassart A; Zaffalon L; Martinon F
Cell Death Dis; 2022 May; 13(5):475. PubMed ID: 35589686
[TBL] [Abstract][Full Text] [Related]
8. Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation.
Jahantigh H; Ahmadi N; Lovreglio P; Stufano A; Enayatkhani M; Shahbazi B; Ahmadi K
J Biomol Struct Dyn; 2023 Jul; 41(11):5057-5066. PubMed ID: 35612907
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.
Chen T; Ho M; Briere J; Moscvin M; Czarnecki PG; Anderson KC; Blackwell TK; Bianchi G
Blood Adv; 2022 Jan; 6(2):429-440. PubMed ID: 34649278
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of FDA approved drugs against
Joshi T; Sharma P; Joshi T; Mathpal S; Pande V; Chandra S
J Biomol Struct Dyn; 2022 May; 40(8):3731-3744. PubMed ID: 33251976
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
[TBL] [Abstract][Full Text] [Related]
12.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
13.
El-Hddad S; Sobhy M; Ayoub A; El-Adl K
J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
[TBL] [Abstract][Full Text] [Related]
14. Drug repurposing against the RNA-dependent RNA polymerase domain of dengue serotype 3 by virtual screening and molecular dynamics simulations.
Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Jul; 41(11):5152-5165. PubMed ID: 35642087
[TBL] [Abstract][Full Text] [Related]
15. DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1.
Dirac-Svejstrup AB; Walker J; Faull P; Encheva V; Akimov V; Puglia M; Perkins D; Kümper S; Hunjan SS; Blagoev B; Snijders AP; Powell DJ; Svejstrup JQ
Mol Cell; 2020 Jul; 79(2):332-341.e7. PubMed ID: 32521225
[TBL] [Abstract][Full Text] [Related]
16. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
17. Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Tian X; Ye J; Alonso-Basanta M; Hahn SM; Koumenis C; Dorsey JF
J Biol Chem; 2011 Aug; 286(33):29408-29416. PubMed ID: 21697087
[TBL] [Abstract][Full Text] [Related]
18. A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2.
Chakraborty J; Maity A; Sarkar H
J Biomol Struct Dyn; 2023 Feb; 41(2):550-559. PubMed ID: 34844509
[TBL] [Abstract][Full Text] [Related]
19. The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma.
Peñaranda Fajardo NM; Meijer C; Kruyt FA
Biochem Pharmacol; 2016 Oct; 118():1-8. PubMed ID: 27106078
[TBL] [Abstract][Full Text] [Related]
20. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
